Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Patients With Glioblastoma Multiforme
OBJECTIVES: I. Determine the efficacy acridine carboxzmide in terms of objective response
rate and response duration in patients with glioblastoma multiforme. II. Determine the
toxicities of this treatment regimen in this patient population.
OUTLINE: This is a multicenter study. Patients receive acridine carboxamide IV continuously
over days 1-5. Treatment repeats every 3 weeks for at least 2 courses and up to a maximum of
6 courses in the absence of disease progression or unacceptable toxicity. Patients are
followed every 6 weeks until disease progression.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Primary Purpose: Treatment
Chris Twelves, MD, BMedSci, FRCP
University of Glasgow
United States: Federal Government